Treatment.com AI Provides an Update on the Status of Exercised Warrants
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) has provided an update on the exercising of warrants issued upon conversion of special warrants on June 21, 2024. Nearly 800,000 warrants have been exercised, raising gross proceeds of approximately half a million dollars. The remaining warrants could potentially bring in over $2 million in additional funds.
CEO Dr. Essam Hamza highlighted that this cash injection will enable the company to expedite its plans, including the launch of 'AI Patient' and 'AI Doctor in the Pocket' products this fall. Treatment.com AI also has a strong acquisition pipeline under review, which could accelerate their growth strategy. The company's core product is the Global Library of Medicine (GLM), an AI-driven healthcare engine providing clinical information with >92% accuracy on first diagnosis.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha fornito un aggiornamento sull'esercizio dei diritti di opzione emessi a seguito della conversione di diritti speciali il 21 giugno 2024. Quasi 800.000 diritti di opzione sono stati esercitati, raccogliendo proventi lordi di circa mezzo milione di dollari. I diritti di opzione rimanenti potrebbero portare oltre 2 milioni di dollari in fondi aggiuntivi.
Il CEO Dr. Essam Hamza ha sottolineato che questo apporto di liquidità consentirà all'azienda di accelerare i propri piani, inclusi il lancio dei prodotti 'AI Patient' e 'AI Doctor in the Pocket' questo autunno. Treatment.com AI ha anche un forte portafoglio di acquisizioni in fase di revisione, che potrebbe velocizzare la loro strategia di crescita. Il prodotto principale dell'azienda è la Global Library of Medicine (GLM), un motore sanitario basato su AI che fornisce informazioni cliniche con un'accuratezza superiore al 92% nella prima diagnosi.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) ha proporcionado una actualización sobre el ejercicio de las opciones emitidas tras la conversión de garantías especiales el 21 de junio de 2024. Casi 800,000 opciones han sido ejercitadas, generando ingresos brutos de aproximadamente medio millón de dólares. Las opciones restantes podrían traer más de 2 millones de dólares en fondos adicionales.
El CEO Dr. Essam Hamza destacó que esta inyección de efectivo permitirá a la empresa acelerar sus planes, incluyendo el lanzamiento de productos como 'AI Patient' y 'AI Doctor in the Pocket' este otoño. Treatment.com AI también tiene un fuerte pipeline de adquisiciones en revisión, lo que podría acelerar su estrategia de crecimiento. El producto principal de la empresa es la Global Library of Medicine (GLM), un motor de atención médica impulsado por IA que proporciona información clínica con más del 92% de precisión en el primer diagnóstico.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF)는 2024년 6월 21일에 발행된 특별 보증서의 전환에 따른 워런트 행사에 대한 업데이트를 제공했습니다. 거의 800,000개의 워런트가 행사되었습니다, 이로 인해 약 50만 달러의 총 수익이 발생했습니다. 남아 있는 워런트는 200만 달러 이상의 추가 자금을 가져올 수 있습니다.
CEO 드 에사므 함자 박사는 이 현금 주입이 회사가 계획을 가속화할 수 있도록 할 것이라고 강조했습니다. 여기에는 이번 가을 'AI Patient' 및 'AI Doctor in the Pocket' 제품의 출시가 포함됩니다. Treatment.com AI는 또한 강력한 인수 파이프라인을 검토 중이며, 이는 그들의 성장 전략을 가속화할 수 있습니다. 회사의 핵심 제품은 Global Library of Medicine (GLM)으로, 1차 진단에 대해 92% 이상의 정확도로 임상 정보를 제공하는 AI 기반의 의료 엔진입니다.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) a fourni une mise à jour sur l'exercice des bons émis lors de la conversion de bons spéciaux le 21 juin 2024. Près de 800 000 bons ont été exercés, générant des recettes brutes d'environ un demi-million de dollars. Les bons restants pourraient potentiellement rapporter plus de 2 millions de dollars de fonds supplémentaires.
Le PDG Dr. Essam Hamza a souligné que cette injection de liquidités permettra à l'entreprise de présenter ses projets plus rapidement, y compris le lancement des produits 'AI Patient' et 'AI Doctor in the Pocket' cet automne. Treatment.com AI dispose également d'un solide pipeline d'acquisitions en cours d'examen, ce qui pourrait accélérer leur stratégie de croissance. Le produit phare de l'entreprise est la Global Library of Medicine (GLM), un moteur de santé basé sur l'IA fournissant des informations cliniques avec une précision supérieure à 92 % lors du premier diagnostic.
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF) hat ein Update zum Ausüben der bei der Umwandlung von Spezialrechten am 21. Juni 2024 ausgegebenen Optionen bereitgestellt. Fast 800.000 Optionen wurden ausgeübt, was zu Bruttoeinnahmen von etwa eine halbe Million Dollar geführt hat. Die verbleibenden Optionen könnten über 2 Millionen Dollar an zusätzlichen Mitteln einbringen.
CEO Dr. Essam Hamza betonte, dass dieser Geldzufluss dem Unternehmen ermöglichen wird, seine Pläne zu beschleunigen, einschließlich der Einführung der Produkte 'AI Patient' und 'AI Doctor in the Pocket' in diesem Herbst. Treatment.com AI hat außerdem eine starke Akquisitionspipeline, die überprüft wird und die ihre Wachstumsstrategie beschleunigen könnte. Das Hauptprodukt des Unternehmens ist die Global Library of Medicine (GLM), eine auf KI basierende Gesundheitsengine, die klinische Informationen mit einer Genauigkeit von über 92 % bei der ersten Diagnose bereitstellt.
- Nearly 800,000 warrants exercised, raising approximately $500,000
- Remaining warrants could potentially bring in over $2 million
- Plans to launch 'AI Patient' and 'AI Doctor in the Pocket' products in fall 2024
- Strong acquisition pipeline under review for potential accelerated growth
- Global Library of Medicine (GLM) AI engine provides >92% accuracy on first diagnosis
- None.
●~800,000 warrants exercised since free trading was announced raising close to half a million dollars.
●Remaining warrants could bring over
●Robust acquisition pipeline
VANCOUVER, British Columbia, July 24, 2024 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the “Company” or “Treatment”), a healthcare tech company transforming patient care with AI-driven clinical insights is pleased to provide the market with an update on the exercising of the warrants which were issued upon conversion of the special warrants on June 21, 2024.
Since the special warrant conversion, the Company is thrilled to announce that almost 800,000 warrants have been exercised raising gross proceeds approximating to half a million dollars.
Dr. Essam Hamza, CEO of Treatment.com AI, comments: “These warrant exercises underscore the strong investor support for our company. The cash injection enables us to expedite our plans at a time when both the investor and healthcare markets are looking for credible AI solutions to mitigate the challenges faced by our healthcare systems. Apart from our previously announced plans to launch our “AI Patient” and “AI Doctor in the Pocket'' products this fall, we also have a strong acquisition pipeline under review that could provide an accelerated timeline for our growth strategy. We look forward to the exercising of the remaining warrants which could bring another
About Treatment.com AI Inc.
Treatment.com AI is a company utilizing AI to positively disrupt the healthcare sector and impact current inefficiencies and challenges. Over the past 7+ years and with the input of hundreds of healthcare professionals globally, Treatment.com AI has built the world’s most intelligent, personalized healthcare AI engine, the Global Library of Medicine (GLM). Providing the highest qualified clinical information and support to all healthcare professionals, the GLM delivers >
FOR ADDITIONAL INFORMATION, CONTACT:
Dr. Essam Hamza, CEO
If you would like to find out more about Treatment’s products and services, please email at info@treatment.com
For media inquiries, contact: media@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Cautionary Statements
This news release contains forward-looking statements that are based on Treatment.com AI’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to the implementation of its shareholder communications initiative and the timing thereof. Although Treatment.com believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements, and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Treatment.com undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
![](https://ml.globenewswire.com/media/YjBlYzhkNTMtYTY2Yi00NDEzLTkzYjQtYTE3Mjc2ZGQ1ZGRhLTUwMDEyMTk0OQ==/tiny/Treatment-com-AI-Inc-.png)
FAQ
How many warrants have been exercised for Treatment.com AI (TREIF) as of July 24, 2024?
How much money has Treatment.com AI (TREIF) raised from exercised warrants?
What potential additional funds could Treatment.com AI (TREIF) receive from remaining warrants?
What products is Treatment.com AI (TREIF) planning to launch in fall 2024?